Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday

Viridian Therapeutics (NASDAQ:VRDN) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $16.2090 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same period in the previous year, the firm earned ($0.81) earnings per share. Viridian Therapeutics’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Trading Down 2.4%

VRDN stock traded down $0.57 during trading on Tuesday, reaching $22.58. 312,124 shares of the stock were exchanged, compared to its average volume of 932,021. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average price of $20.75 and a 200-day moving average price of $17.23. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $27.20. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -5.87 and a beta of 0.49.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 454,545 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was purchased at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director owned 3,914,458 shares of the company’s stock, valued at approximately $86,118,076. This trade represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.58% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Viridian Therapeutics by 37.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 190,229 shares of the company’s stock worth $2,659,000 after acquiring an additional 51,365 shares in the last quarter. Boothbay Fund Management LLC grew its holdings in Viridian Therapeutics by 25.6% during the 2nd quarter. Boothbay Fund Management LLC now owns 182,452 shares of the company’s stock worth $2,551,000 after acquiring an additional 37,134 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after acquiring an additional 14,788 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Viridian Therapeutics during the 2nd quarter worth approximately $1,671,000. Finally, Rhumbline Advisers grew its holdings in Viridian Therapeutics by 2.7% during the 2nd quarter. Rhumbline Advisers now owns 107,385 shares of the company’s stock worth $1,501,000 after acquiring an additional 2,826 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on VRDN shares. Oppenheimer lifted their target price on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of Viridian Therapeutics in a research report on Monday, August 25th. They set a “buy” rating and a $44.00 price target for the company. Royal Bank Of Canada dropped their price target on shares of Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, Wells Fargo & Company dropped their price target on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.22.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.